New Zealand Government Grants $650K For LSD Microdosing Trials
Cannabis Law Report
JULY 25, 2022
Mindbio Therapeutics , a subsidiary of cannabis and psychedelics holding company Blackhawk Growth Corp. million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). Press Release.
Let's personalize your content